BIOMAT Database Logo BIOMAT Database Logo

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. 2020

Chee Wah Tan, and Wan Ni Chia, and Xijian Qin, and Pei Liu, and Mark I-C Chen, and Charles Tiu, and Zhiliang Hu, and Vivian Chih-Wei Chen, and Barnaby E Young, and Wan Rong Sia, and Yee-Joo Tan, and Randy Foo, and Yongxiang Yi, and David C Lye, and Danielle E Anderson, and Lin-Fa Wang
Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.

A robust serological test to detect neutralizing antibodies to SARS-CoV-2 is urgently needed to determine not only the infection rate, herd immunity and predicted humoral protection, but also vaccine efficacy during clinical trials and after large-scale vaccination. The current gold standard is the conventional virus neutralization test requiring live pathogen and a biosafety level 3 laboratory. Here, we report a SARS-CoV-2 surrogate virus neutralization test that detects total immunodominant neutralizing antibodies targeting the viral spike (S) protein receptor-binding domain in an isotype- and species-independent manner. Our simple and rapid test is based on antibody-mediated blockage of the interaction between the angiotensin-converting enzyme 2 (ACE2) receptor protein and the receptor-binding domain. The test, which has been validated with two cohorts of patients with COVID-19 in two different countries, achieves 99.93% specificity and 95-100% sensitivity, and differentiates antibody responses to several human coronaviruses. The surrogate virus neutralization test does not require biosafety level 3 containment, making it broadly accessible to the wider community for both research and clinical applications.

UI MeSH Term Description Entries
D007703 Peptidyl-Dipeptidase A A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, oligopeptide-|-Xaa-Yaa, when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion of ANGIOTENSIN I to ANGIOTENSIN II, with increase in vasoconstrictor activity, but no action on angiotensin II. It is also able to inactivate BRADYKININ, a potent vasodilator; and has a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. (From https://www.uniprot.org April 15, 2020). ACE1 Angiotensin-Converting Enzyme 1,ACE1 Protein,Angiotensin Converting Enzyme,Angiotensin Converting Enzyme 1,Antigens, CD143,CD143 Antigens,Dipeptidyl Carboxypeptidase I,Kininase II,Peptidase P,Angiotensin I-Converting Enzyme,Carboxycathepsin,Dipeptidyl Peptidase A,Kininase A,ACE1 Angiotensin Converting Enzyme 1,Angiotensin I Converting Enzyme,Carboxypeptidase I, Dipeptidyl,Peptidyl Dipeptidase A
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D011024 Pneumonia, Viral Inflammation of the lung parenchyma that is caused by a viral infection. Pneumonias, Viral,Viral Pneumonia,Viral Pneumonias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000073640 Betacoronavirus A genus of the family CORONAVIRIDAE which causes respiratory or gastrointestinal disease in a variety of mostly mammals. Human betacoronaviruses include HUMAN ENTERIC CORONAVIRUS; HUMAN CORONAVIRUS OC43; MERS VIRUS; and SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS. Members have either core transcription regulatory sequences of 5’-CUAAAC-3’ or 5’-CUAAAC-3’ and mostly have no ORF downstream to the N protein gene. HCoV-HKU1,Human coronavirus HKU1,Pipistrellus bat coronavirus HKU5,Rousettus bat coronavirus HKU9,Tylonycteris bat coronavirus HKU4,Betacoronaviruses
D000085962 Angiotensin-Converting Enzyme 2 A transmembrane glycoprotein with an extracellular catalytic domain which functions as a carboxypeptidase. It cleaves a single C-terminal residue from a distinct range of substrates. The catalytic efficiency is 400-fold higher with ANGIOTENSIN II as a substrate than with ANGIOTENSIN I. Angiotensin-converting enzyme 2 is also is a functional receptor for the spike glycoprotein (SPIKE PROTEIN, CORONAVIRUS) of the CORONAVIRUSES SARS-COV, SARS-COV2, and HCOV-NL63. ACE-Related Carboxypeptidase,ACE2 Angiotensin-Converting Enzyme Protein 2,ACE2 Enzyme,ACE2 Protein,Angiotensin Converting Enzyme 2,Angiotensin-Converting Enzyme-Related Carboxypeptidase,ACE Related Carboxypeptidase,ACE2 Angiotensin Converting Enzyme Protein 2,Angiotensin Converting Enzyme Related Carboxypeptidase,Carboxypeptidase, ACE-Related,Carboxypeptidase, Angiotensin-Converting Enzyme-Related
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000906 Antibodies Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
D054730 Protein Interaction Domains and Motifs Protein modules with conserved ligand-binding surfaces which mediate specific interaction functions in SIGNAL TRANSDUCTION PATHWAYS and the specific BINDING SITES of their cognate protein LIGANDS. Protein Interaction Domains,Protein Interaction Motifs,Binding Motifs, Protein Interaction,Protein Interaction Binding Motifs,Protein-Protein Interaction Domains,Domain, Protein Interaction,Domain, Protein-Protein Interaction,Domains, Protein Interaction,Domains, Protein-Protein Interaction,Motif, Protein Interaction,Motifs, Protein Interaction,Protein Interaction Domain,Protein Interaction Motif,Protein Protein Interaction Domains,Protein-Protein Interaction Domain

Related Publications

Chee Wah Tan, and Wan Ni Chia, and Xijian Qin, and Pei Liu, and Mark I-C Chen, and Charles Tiu, and Zhiliang Hu, and Vivian Chih-Wei Chen, and Barnaby E Young, and Wan Rong Sia, and Yee-Joo Tan, and Randy Foo, and Yongxiang Yi, and David C Lye, and Danielle E Anderson, and Lin-Fa Wang
Fast and Accurate Surrogate Virus Neutralization Test Based on Antibody-Mediated Blocking of the Interaction of ACE2 and SARS-CoV-2 Spike Protein RBD.
February 2022, Diagnostics (Basel, Switzerland),
Chee Wah Tan, and Wan Ni Chia, and Xijian Qin, and Pei Liu, and Mark I-C Chen, and Charles Tiu, and Zhiliang Hu, and Vivian Chih-Wei Chen, and Barnaby E Young, and Wan Rong Sia, and Yee-Joo Tan, and Randy Foo, and Yongxiang Yi, and David C Lye, and Danielle E Anderson, and Lin-Fa Wang
Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig.
April 2020, Nature communications,
Chee Wah Tan, and Wan Ni Chia, and Xijian Qin, and Pei Liu, and Mark I-C Chen, and Charles Tiu, and Zhiliang Hu, and Vivian Chih-Wei Chen, and Barnaby E Young, and Wan Rong Sia, and Yee-Joo Tan, and Randy Foo, and Yongxiang Yi, and David C Lye, and Danielle E Anderson, and Lin-Fa Wang
Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test.
December 2021, One health (Amsterdam, Netherlands),
Chee Wah Tan, and Wan Ni Chia, and Xijian Qin, and Pei Liu, and Mark I-C Chen, and Charles Tiu, and Zhiliang Hu, and Vivian Chih-Wei Chen, and Barnaby E Young, and Wan Rong Sia, and Yee-Joo Tan, and Randy Foo, and Yongxiang Yi, and David C Lye, and Danielle E Anderson, and Lin-Fa Wang
Identification and characterization of a monoclonal antibody blocking the SARS-CoV-2 spike protein-ACE2 interaction.
June 2021, Cellular & molecular immunology,
Chee Wah Tan, and Wan Ni Chia, and Xijian Qin, and Pei Liu, and Mark I-C Chen, and Charles Tiu, and Zhiliang Hu, and Vivian Chih-Wei Chen, and Barnaby E Young, and Wan Rong Sia, and Yee-Joo Tan, and Randy Foo, and Yongxiang Yi, and David C Lye, and Danielle E Anderson, and Lin-Fa Wang
A simple protein-based surrogate neutralization assay for SARS-CoV-2.
October 2020, JCI insight,
Chee Wah Tan, and Wan Ni Chia, and Xijian Qin, and Pei Liu, and Mark I-C Chen, and Charles Tiu, and Zhiliang Hu, and Vivian Chih-Wei Chen, and Barnaby E Young, and Wan Rong Sia, and Yee-Joo Tan, and Randy Foo, and Yongxiang Yi, and David C Lye, and Danielle E Anderson, and Lin-Fa Wang
Quantitative SARS-CoV-2 Spike Antibody Response in COVID-19 Patients Using Three Fully Automated Immunoassays and a Surrogate Virus Neutralization Test.
August 2021, Diagnostics (Basel, Switzerland),
Chee Wah Tan, and Wan Ni Chia, and Xijian Qin, and Pei Liu, and Mark I-C Chen, and Charles Tiu, and Zhiliang Hu, and Vivian Chih-Wei Chen, and Barnaby E Young, and Wan Rong Sia, and Yee-Joo Tan, and Randy Foo, and Yongxiang Yi, and David C Lye, and Danielle E Anderson, and Lin-Fa Wang
A Neutralization Assay Based on Pseudo-Typed Lentivirus with SARS CoV-2 Spike Protein in ACE2-Expressing CRFK Cells.
February 2021, Pathogens (Basel, Switzerland),
Chee Wah Tan, and Wan Ni Chia, and Xijian Qin, and Pei Liu, and Mark I-C Chen, and Charles Tiu, and Zhiliang Hu, and Vivian Chih-Wei Chen, and Barnaby E Young, and Wan Rong Sia, and Yee-Joo Tan, and Randy Foo, and Yongxiang Yi, and David C Lye, and Danielle E Anderson, and Lin-Fa Wang
A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction.
August 2020, Nature communications,
Chee Wah Tan, and Wan Ni Chia, and Xijian Qin, and Pei Liu, and Mark I-C Chen, and Charles Tiu, and Zhiliang Hu, and Vivian Chih-Wei Chen, and Barnaby E Young, and Wan Rong Sia, and Yee-Joo Tan, and Randy Foo, and Yongxiang Yi, and David C Lye, and Danielle E Anderson, and Lin-Fa Wang
Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry.
January 2021, Nature communications,
Chee Wah Tan, and Wan Ni Chia, and Xijian Qin, and Pei Liu, and Mark I-C Chen, and Charles Tiu, and Zhiliang Hu, and Vivian Chih-Wei Chen, and Barnaby E Young, and Wan Rong Sia, and Yee-Joo Tan, and Randy Foo, and Yongxiang Yi, and David C Lye, and Danielle E Anderson, and Lin-Fa Wang
Antibody-mediated neutralization of SARS-CoV-2.
June 2022, Immunity,
Copied contents to your clipboard!